Avidin was established in 2002 and has a drug discovery pipeline in the field of cancer, inflammation and CNS.The company is a service provider for biotech and pharma companies in the field of medicinal chemistry, screen development, target identification, high-throughput genomics, diagnostics, in vivo efficacy and toxicology. Avidin is a local distributor of several companies over the world and sales molecular diagnostic kits for early detection of different pathogens.
Avidin’s drug discovery pipeline includes drug candidates for cancer, inflammation and CNS diseases.
Researchers at Avidin have synthesized analogues of novel quinoline analogues may have potential applications in amnesia and Alzheimer’s disease. The IP held by Avidin on the novel structure and its application is valuable, offering the possibility of widening the application of the drug candidate. Kinolol compounds exert neuroprotective action in vitro, they orally active as anti-anxiety drugs in vivo and possesses procognitive effects. Kinolol exhibited activity in scopolamine-induced amnesia model and Alzheimer’s disease animal models. After finishing preclinical studies Phase I clinical trial will be initiated in early 2015.
Avidin has synthesized more than 80 curcumin analogs with novel scaffold. Analogues have been optimized for better anticancer and efficacy in vivo. Moreover C-150 synergized with bortezomib and cytarabine in vitro as well as in vivo (AML model). Curcumid showed toxic side effects at above 30 mg/kg dose in acute experiments. Curcumid decreases nuclear factor KB activation, induces autophagy and ER stress through GRP78 and GADD153. Curcumid as a multitarget agent also inhibits the Akt/mTOR/p70S6K pathway. Another class of curcumin analogs for better cytoprotection profiles were developed and found to be active in colitis rat model.
The company is a service provider for biotech and pharma companies in the field of medicinal chemistry, screen development, target identification, high-throughput genomics, diagnostics, in vivo efficacy and toxicology.
Non-GLP toxicology, inflammation, cancer and CNS models
A) Traditional pathological examination, LD50 determination in general or focused on organ-specific manifestations.
Rat, mouse, dog
Acute and chronic non-GLP toxicology in a cos-effective way.
B) Toxicogenomics analysis of tissue- and organ-specific gene markers on nanocapillary HTS QRT-PCR panels. Expression of 56 genes are followed after in vivo administration of drugs in mouse liver heart, brain and kidney. Tissue-specific toxicity is predicted based on 1344 gene expression data.
The company performs POC studies in acute inflammation models (arthritis, colitis) and behaviour tests for cognition (amnesia, Y-maze, novel object recognition, nesting).
In an SPF-like animal facility Avidin has optimized several cancer xenograft models, including, glioblastoma, liver, lung, breast, prostate cancers and melanoma.
Screening & Medicinal chemistry
IDENTIFY HIT MOLECULES FOR YOUR DRUG TARGET
Avidin has recently set up a label-free screening laboratory, where three cutting edge technologies were established, the Enspire plate reader from Perkin Elmer, the xCelligence system from Roche/Acea and the holographic microscopy from Phiab.
Besides using these technologies for in-house screening programmes, Avidin provides the following services:
Real-time measurements of the cytotoxic effects of small molecules/mixtures/extracts on primary cells or cancer cells in a medium high throughput manner.
Determination of G-protein coupled receptor interaction of small molecules/mixtures/extracts in a medium high-throughput manner.
Providing hit molecules (Kd about 1 µM) (binders, inhibitors, inducers) for drug targets in a medium highthroughput manner.
PROVIDE THE NAME OF THE TARGET, AND WE GIVE YOU PATENTABLE NCEs AND CORE STRUCTURES WITHIN 1-2 MONTHS
The MouSafeTM Panels developed at Avidin are powerful, cost-effective diagnostic tools for regular mouse colony screening. Avidin performs three different panels using highly specific, fast, sensitive Real-time PCR test protocols.